NEW YORK, NY / ACCESSWIRE / February 17, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm
focused on smallcap and microcap public companies, today announced it has initiated coverage on BioSig Technologies, Inc. (OTC:
BSGM) with a Price Target of $3.53.
The report is available here: BSGM Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First
Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to
Thomson Estimates, the leading estimates platform on Wall Street.
Based in Minneapolis, MN, BioSig is an innovative medical device company developing products with the potential to improve
outcomes for patients with complex cardiac arrhythmias (heart rhythm disturbances). BioSig is focused on commercializing products
for the $3.5 billion global market for electrophysiology (EP), the science of testing electrical activity in the heart to identify
the cause and nature of arrhythmias. The company's flagship product line, the PURE EP(TM) System, is intended to drastically
improve the process of identifying catheter ablation targets - areas of tissue to destroy that otherwise create a cardiac
arrhythmia. Using BioSig's proprietary hardware and software, PURE EP(TM) System promises to be a wide-sweeping technology refresh
for the EP market, offering superior performance versus existing EP recording systems. Indeed, PURE EP(TM) enables the detection of
previously undetected intracardiac (IC) signals, facilitates real time analysis of the nature of arrhythmia using multiple windows,
and providing a high fidelity signal - all of which have the potential to improve the identification, diagnosis, and understanding
of arrhythmias while reducing ablation procedure times and lowering the frequency with which arrhythmia patients must undergo
repeat procedures.
"We see several catalysts ahead for BioSig in 2016E on both corporate and clinical fronts. The company completed three
encouraging pre-clinical studies during 2015 with prestigious institutional partners including the Mayo Clinic, and has indicated
that it expects at least one Mayo study to be published in a high profile medical journal during 1H16E, which we reason has the
potential to attract the attention of both investors and industry leaders. Additionally, BioSig is seeking 510(k) FDA clearance for
PURE EP, which it expects to be complete by the end of 2016E or early 2017E. On the corporate front, BioSig recently made several
impressive additions to its management team and Board of Directors, and management has also indicated that it is pursuing a NASDAQ
listing during 2016E. If the company is tracking to plan with this initiative, we would expect new financing as part of the
up-listing, as well as strategic partner and distribution announcements as the company prepares to commercialize PURE EP(TM) in
2017," stated Ajay Tandon, CEO of SeeThruEquity. "We are initiating coverage with a 12-month price target of $3.53 per share."
Additional highlights from the report are as follows:
2016 promises to be a pivotal year for BioSig
We see several catalysts ahead for BioSig in 2016 on both corporate and clinical fronts. The company completed three encouraging
pre-clinical studies for its flagship PURE EP(TM) System during 2015 with prestigious institutional partners including the Mayo
Clinic, and has indicated that it expects at least one Mayo study to be published in a high profile medical journal during 1H16E.
In our view, the publication of the preclinical studies is an important catalyst for BioSig with the potential to attract positive
attention from both investors and industry leaders. Additionally, BioSig is seeking 510(k) FDA clearance for PURE EP(TM), which it
expects to be complete by early 2017E. Clearly achieving FDA clearance would be a major accomplishment. On the corporate front,
BioSig recently made several impressive additions to its management team and Board of Directors, and management has also indicated
that it is pursuing a NASDAQ listing during 2016E. If the company is tracking to plan with this initiative, we would expect new
financing to be a part of the up-listing, as well as strategic partner and distribution announcements later in the year as the
company prepares to commercialize PURE EP(TM) in 2017.
PURE EP(TM) System a novel step forward in the $3.5 billion EP market
Using BioSig's proprietary hardware and software, the PURE EP(TM) System promises to be a wide-sweeping technology refresh for
the $3.5 billion global EP market - a market that is growing quickly and is expected to reach $5.5 billion by 2019E according to
Global Industry Analysis. PURE EP(TM) is a highly differentiated solution, which offers superior performance and applications
compared to existing EP recording systems. Indeed, PURE EP(TM) enables the detection of previously undetected IC signals,
facilitates real time analysis of the nature of arrhythmia cardiac electrical activity using multiple windows, and provides
high-fidelity signals - all of which have the potential to improve the identification, diagnosis, and understanding of arrhythmias
while reducing ablation procedure times and lowering the frequency with which arrhythmia patients must undergo repeat
procedures.
Please review important disclosures at www.seethruequity.com.
About BioSig Technologies, Inc.
BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the $3
billion electrophysiology (EP) marketplace1 (www.biosigtech.com). Led by a proven management team and a veteran, independent Board
of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System.
PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist
electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings
and providing clarity of data which may be used to guide the EPs in identifying ablation targets -- areas of tissue to treat that
otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in
2012 to $5.5 billion by 2019 - making it one of the fastest growing medical device segments. Just in the US, the number of Atrial
Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017.
BioSig intends to seek FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept validation through
UCLA labs, and has performed pre-clinical studies at the Mayo Clinic in Minnesota. The Company is collaborating with several of the
nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center,
and Mayo Clinic.
1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2) HRI
2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; *AF includes left atrial
tachycardia, left WPW, left atrial flutter.
About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market
capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission
based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet,
Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson
Estimates, the leading estimates platform on Wall Street.
For more information visit www.seethruequity.com.
Contact:
Ajay Tandon SeeThruEquity info@seethruequity.com
SOURCE: SeeThruEquity
